Summit Therapeutics Inc. (SMMT)
NASDAQ (NMS) NASDAQ (NMS) Primary 
XMEX 
Is Summit Therapeutics a Buy Now?
Ivonescimab is a bispecific antibody that targets PD-1 and VEGF to treat lung cancer. In a phase 3 trial, patients treated with ivonescimab were 49% less likely to experience their disease worsening than patients treated with Keytruda.
Why Summit Therapeutics Rocketed Over 60% Today
Summit's lung cancer treatment Ivonescimab outperformed Merck's Keytruda in a Phase III trial. The data were even better than anticipated.
Summit Therapeutics: Positive Data Leads To Targeting Of Other NSCLC Subpopulation
Summit's and Akeso's ivonescimab outperformed Merck's Keytruda in a phase 3 trial for first-line advanced NSCLC, showing significant clinical benefits. Ivonescimab's success against Keytruda in NSCLC positions Summit to capture a large market share in the multibillion-dollar NSCLC indication. Positive trial results opens expansion opportunities for ivonescimab in first-line PD-L1 high advanced NSCLC and eventually other cancer types.
Lung Cancer Drug Trial News Has Summit Therapeutics Stock Up 40% Today
Shares of Summit Therapeutics (SMMT) skyrocketed Monday, rising to an all-time high after the biotech announced positive results from a late-stage trial of its experimental lung cancer treatment.
Biotech Stocks: Lung Cancer Treatment Outflanks Merck's Keytruda
Summit shares jumped Monday after positive late-stage indications vs. Merck's Keytruda.
Summit Therapeutics' Lung Cancer Candidate Surpasses Merck's Multi-Billion Dollar Keytruda, Cuts Risk Of Disease Or Death By Half
Sunday, Summit Therapeutics Inc. SMMT released data from the primary analysis of the Phase 3 HARMONi-2 trial of ivonescimab conducted in China, sponsored by collaboration partner Akeso, Inc.
Summit Therapeutics Inc. (SMMT) Q2 2024 Earnings Call Transcript
Summit Therapeutics Inc. (NASDAQ:SMMT ) Q2 2024 Results Conference Call August 6, 2024 9:00 AM ET Company Participants Dave Gancarz - Chief Business and Strategy Officer Bob Duggan - Chairman and Chief Executive Officer Maky Zanganeh - Chief Executive Officer, President Manmeet Soni - Chief Operating Officer Allen Yang - Chief Medical Officer Conference Call Participants Dara Azar - Stifel Yigal Nochomovitz - Citigroup Mitchell Kapoor - H.C. Wainwright Operator Good morning, and welcome to Summit Therapeutics Second Quarter 2024 Earnings and Update Call.
Summit Therapeutics May Have Further Upside From Here
Summit Therapeutics to release second-quarter earnings and operational update on 6 August. Analysts are bullish on Phase 3 trial results for Ivonescimab in September, with a potential de-risking of the drug's profile. The company boosted its balance sheet with a $200 million institutional capital raise and expanded licensing territories after positive Phase I and II trial results.
Summit (SMMT) Stock Surges 57% in the Past Month: Here's Why
Summit Therapeutics (SMMT) surges after data from a late-stage study shows that its experimental antibody beat Merck's Keytruda in a head-to-head setting in treating certain patients with lung cancer.
Biotech Stock Volatile After Upbeat Trial data
The shares of Summit Therapeutics Inc (NASDAQ:SMMT) appear to be headed for a minor correction after yesterday's skyrocket.
Summit Therapeutics cancer therapy succeeds in late-stage China study
Summit Therapeutics said on Thursday its experimental therapy to treat patients with a type of lung cancer met the main goal of a late-stage study conducted in China.
Why Summit Therapeutics Stock Is Sinking Today
Summit Therapeutics' stock is falling sharply for the second consecutive trading day. The sell-off began after the company revealed disappointing late-state data for its lead pipeline candidate.
